Other skills

Deprecated alias — use `/woz review`.

The English summary is being prepared. Showing the original description.

Deprecated alias — use `/woz login`.

The English summary is being prepared. Showing the original description.

Deprecated alias — use `/woz-kb <op>` (e.g. `/woz-kb status`).

The English summary is being prepared. Showing the original description.

Authenticate with the Woz service. Use when the user needs to log in or when authentication is required.

The English summary is being prepared. Showing the original description.

Deprecated alias — use `/woz update`.

The English summary is being prepared. Showing the original description.

Deprecated alias — use `/woz share`.

The English summary is being prepared. Showing the original description.

Show current Woz authentication status.

The English summary is being prepared. Showing the original description.

Deprecated alias — use `/woz status`.

The English summary is being prepared. Showing the original description.

Medicines pipeline analysis over structured universes: Phase I-III assets with probability-of-success discipline (unadjusted peak x POS = modeled value; POS changes logged with reasons), trial status-diff tracking, and mechanism/competitor mapping via drug-knowledge lookups.

The English summary is being prepared. Showing the original description.

Med-adapted recent-quarter review: last print financials, pipeline-milestone awareness, and FDA-event context — reads the quarter through the med lens (milestones moved, runway, regulatory updates) rather than generic financials alone.

The English summary is being prepared. Showing the original description.

Med peer benchmarking: select actual biotech/pharma peers via the med universe (drug/indication overlap where possible) and compare med-relevant metrics — pipeline depth, catalyst density, cash position, margins, valuation multiples.

The English summary is being prepared. Showing the original description.

Post-event analyst note (conferences, KOL events, site visits) with the professional note anatomy — headline verdict, per-stock takeaways with model numbers, KOL distillation, cross-trial comparison lattices, modeled deltas vs consensus (peak × POS), three what's-changed vectors, risk bullets, and materiality-rated conflicting views. Use after any med event to convert the event into actionable takeaways.

The English summary is being prepared. Showing the original description.

Competitive landscape analysis, competitor comparison, peer positioning, market share dynamics, competitive moat assessment, Porter five forces, industry competition, competitive advantage analysis, market positioning, strategic group mapping, compare competitors

The English summary is being prepared. Showing the original description.

CDER-track catalyst analysis for medicines: PDUFA target dates, AdCom votes, sNDA/sBLA label expansions, biosimilar interchangeability and 180-day exclusivity, Orange Book state, and CRL remediation timelines — enumerated, verified, and sized per event for any biotech/pharma ticker or watchlist.

The English summary is being prepared. Showing the original description.

Device-track catalyst analysis: 510(k), PMA, and De Novo decision events, CMS coverage and NTAP milestones, recalls and watch actions as risk signals, and post-market surveillance obligations — dated, verified, and sized per event for any medtech ticker or watchlist.

The English summary is being prepared. Showing the original description.

Med-adapted earnings preview: consensus estimates, historical surprises, guidance sensitivities, and the FDA-catalyst overlay (PDUFA/AdCom/trial readouts near the print) for biotech/pharma names.

The English summary is being prepared. Showing the original description.

Med-sector overview across med.medicines_biotech and med.medical_devices with med trends, catalysts, FDA-decision context, and a cross-sector ripple map (quantified sign/magnitude per name). Use to frame any biotech/pharma/device analysis before diving into a single name.

The English summary is being prepared. Showing the original description.

Valuation methods analysis, DCF inputs, comparable multiples, P/E ratio, EV/EBITDA, price to book, valuation assumptions, relative valuation, intrinsic value, fair value estimate

The English summary is being prepared. Showing the original description.

Patient-flow market sizing for med products — prevalence → diagnosed → interested → affordable → covered → treated → persistent, priced as price × duration per cohort, with capacity constraints, named historical analog anchoring, and always bull/base/bear named-driver grids. Use to size a therapy area or product market before any valuation or share work.

The English summary is being prepared. Showing the original description.

Recent quarter performance analysis, quarterly earnings review, last quarter results, quarterly financial performance, analyze recent quarter, Q4 earnings, quarterly revenue breakdown, EPS this quarter, margin analysis recent quarter, sequential growth, quarterly performance review

The English summary is being prepared. Showing the original description.

Risk analysis, regulatory risk assessment, competitive risk, macro risk, technology risk, litigation risk, financial risk assessment, enterprise risk, operational risk, geopolitical risk exposure

The English summary is being prepared. Showing the original description.

Secular technology trends, technology adoption cycle, disruption risk, AI impact analysis, digital transformation, industry 4.0 trends, technology moat, innovation trajectory, R&D effectiveness, tech competitive positioning

The English summary is being prepared. Showing the original description.

Find current job postings on employer career pages and job boards. Use when the user asks who's hiring, seeks remote or local jobs, or wants openings matched to their role, skills, experience, or salary preferences.

The English summary is being prepared. Showing the original description.

Monitor competitor pricing, features, changelogs, dashboards, and product changes with Firecrawl. Use for recurring competitive intelligence, pricing tier extraction, feature change tracking, or structured competitor alerts.

The English summary is being prepared. Showing the original description.